fda warning letters compounded semaglutide tirzepatide 2025 Compound versions of GLP-1 drugs for weight loss halted by Novo Nordisk calls out dangers

Key Takeaways Weight loss plateaus on Semaglutide are a normal metabolic adaptation, typically occurring between 20 and 60 weeks of treatment

Obesity brings increased risk for other diseases such as diabetes, heart disease, cancer, or even stroke

To enhance aqueous solubility, Gln 23 was replaced with glutamic acid, which also removed the potential for deamidation

The most number of times a cardiologist has mentioned urine and measuring something in the urine

If you are currently using Wegovy and find out that youre pregnant, speak with your healthcare provider and explain that you are pregnant so that they can weigh the risks and benefits of continuing treatment with Wegovy or switching to a different medication or treatment course